Understanding Cardiometabolic Diseases Through Transcriptomic Approach

Transcriptomics, focusing on ribonucleic acid (RNA) molecules in cells, provides insights into gene expression’s molecular mechanisms, aiding in disease understanding, functional genomics, and responses to stimuli. Technologies like RNA-sequencing (RNA-seq) revolutionize transcriptome analysis, enabling deep exploration of non-coding RNA and gene expression dynamics, shaping medical, environmental, and developmental research. Primarily through RNA-seq, transcriptomics has transformed gene expression research, enabling advancements like single-cell investigations and long-read sequencing. Integrating transcriptomics with other omics data unveils regulatory networks and functional relationships, elucidating disease mechanisms and biological processes. Cardiometabolic diseases, including cardiovascular diseases, diabetes, kidney disease, and liver disease, are preventable conditions whose molecular underpinnings are elucidated by transcriptomics, identifying biomarkers, clarifying gene-environment interactions, and guiding personalized treatments. Transcriptomics is pivotal in understanding and managing cardiometabolic diseases, offering insights into biomarkers, treatment targets, and disease mechanisms. Challenges include integration with other omics techniques, tissue-specific gene expression detection, sample heterogeneity, and limited validation of non-coding RNA biomarkers. Nonetheless, transcriptomics provides insights into disease mechanisms and therapies. Future perspectives include multi-omics integrationPotential therapeutic strategies in metabolic syndrome managementmulti-omics integration, single-cell analysis, and personalized medicine, enhancing understanding and treatment strategies.